News

Scottsdale, Arizona June 7, 2018 – Hope Pharmaceuticals today announced that the company filed a Supplemental New Drug Application to the United States Food and Drug Administration (FDA) for the use of Sodium Thiosulfate Injection to prevent a potential complication associated with the administration of a chemotherapeutic agent.

Scottsdale, Arizona June 5, 2018 – Hope Pharmaceuticals today announced enrollment of the first Canadian subject to participate in the CALISTA clinical study that is evaluating Sodium Thiosulfate Injection for the treatment of calciphylaxis (calcify uremic arteriolopathy, CUA).

This website is intended for informational purposes only and not intended to replace discussion with a healthcare provider. The content of this website is not and should not be construed as medical advice. If you have questions about a particular medical issue, you should contact a healthcare provider. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222.

This website is intended for residents of the United States of America (USA) only and is subject to applicable U.S. laws and regulations. If you have any questions regarding the content of this website, please contact Hope Pharmaceuticals.